This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pell, J. M. Articles by Flick-Smith, H. C. Search for Related Content PubMed PubMed Citation Articles by Pell, J. M. Articles by Flick-Smith, H. C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CYSTEINE L-SERINE

Enhancement of Insulin-Like Growth Factor I Activity by Novel Antisera: Potential Structure/Function Interactions¹

The Babraham Institute, Cambridge, United Kingdom CB2 4AT

Address all correspondence and requests for reprints to: Dr. J. M. Pell, The Babraham Institute, Cambridge, United Kingdom CB2 4AT. E-mail: jenny.pell{at}bbsrc.ac.uk

Insulin-like growth factor I (IGF-I) is essential for normal growth and development, regulating cell proliferation, differentiation, and survival. Little IGF-I exists in the free form; rather, it is bound to one of a family of six specific IGF-binding proteins (IGFBPs). Usually, IGFBPs have a high affinity for IGF-I and inhibit its activity. Intriguingly, some IGFBPs also potentiate IGF-I action; the precise mechanism of this is unclear, but it is thought to include modification of the IGFBP to lower its affinity for IGF-I. We have previously generated a novel antihuman (h) IGF-I antiserum that, instead of inhibiting IGF-I activity, enhances it in vivo. As the enhancing anti-IGF-I antiserum and potentiating IGFBPs share several properties with regard to IGF action, the antibody may provide a model for examining the actions of enhancing IGFBPs. In this study we demonstrate that the antiserum can also enhance IGF-I activity in vitro, assessed as cell number of a bovine fibroblast cell line, suggesting that its actions might not merely be confined to changing the kinetics of IGF-I clearance or degradation. Epitope scanning using overlapping octamer and hexamer peptides spanning the entire sequence of IGF-I indicates that the enhancing antiserum recognizes a specific linear region spanning the C-terminal region of the C domain and the proximal A domain (residues Ser³³ to Cys⁴⁷), and that this recognition is not present in nonenhancing antisera. Further, this region is located on the opposite surface of IGF-I from putative type 1 receptor-binding residues, allowing the possibility that the antiserum might be able to modulate IGF-I receptor binding. Antibodies raised against a synthetic peptide corresponding to Ser³³ to Cys⁴⁷ of IGF-I also potentiated IGF-I activity in vivo. As IGF-I may be beneficial in various clinical conditions associated with catabolism or cell repair, we suggest that this potentiating anti-IGF-I antiserum has favorable properties that could form a basis for therapeutic strategy.

This article has been cited by other articles:

				R. A. Hill, D. J. Flint, and J. M. Pell Antibodies as molecular mimics of biomolecules: roles in understanding physiological functions and mechanisms Advan Physiol Educ, December 1, 2008; 32(4): 261 - 273. [Abstract] [Full Text] [PDF]

				D. L. Smith, B. M. Stinefelt, K. P. Blemings, and M. E. Wilson Diet-induced alterations in progesterone clearance appear to be mediated by insulin signaling in hepatocytes J Anim Sci, May 1, 2006; 84(5): 1102 - 1109. [Abstract] [Full Text] [PDF]